Evidence map›Paper›PMID 41936467›Full record

ArticleBreast (Edinburgh, Scotland)2026

Corrigendum to "Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer" [The Breast 86 (2026) 104744].

Adam Brufsky, Rachel M Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B Cohen, Melissa Estevez, Paul Cottu, Giuseppe Curigliano, Hope S Rugo

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Adam BrufskyDivision of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: brufskyam@upmc.edu.
Rachel M LaymanDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xianchen LiuUS Oncology Medical Affairs, Pfizer Inc, New York, NY, USA.
Benjamin LiGlobal Biometrics & Data Management, Pfizer Inc, New York, NY, USA.
Lynn McRoyUS Oncology Medical Affairs, Pfizer Inc, New York, NY, USA.
Aaron B CohenFlatiron Health Inc., New York, NY, USA.
Melissa EstevezFlatiron Health Inc., New York, NY, USA.
Paul CottuDepartment of Medical Oncology & Institute of Women Cancers, Institut Curie, Université Paris Cité, Paris, France.
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milano, Milano, Italy; European Institute of Oncology (IEO) IRCCS, Milano, Italy.
Hope S RugoBreast Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41936467
PMCPMC13184477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.